| Identification | Back Directory | [Name]
GLYX 13 | [CAS]
117928-94-6 | [Synonyms]
GLYX 13
GIYX-13
CS-1640
Rapastinel
TPPT-amide
GLYX 13 TFA
UNII-6A1X56B95E
NRX-1074 GLYX-13
GLYX13(Rapastinel)
Thr-Pro-Pro-Thr-NH2
Rapastinel(GLYX-13)
GLYX-13;GLYX 13;GLYX13
GLYX-13 trifluoroacetate
TPPT-amide trifluoroacetate
Rapastinel (GLYX-13) acetate
GLYX-13 trifluoroacetate,Rapastinel
Thr-Pro-Pro-Thr-NH2 trifluoroacetate
GLYX-13;GLYX13;GLYX 13;THR-PRO-PRO-THR-NH2
L-Threonyl-L-prolyl-L-prolyl-L-threoninamide
Rapastinel,GLYX-13,Thr-Pro-Pro-Thr-NH2, >99%
L-ThreoninaMide, L-threonyl-L-prolyl-L-prolyl-
L-Threonyl-L-prolyl-L-prolyl-L-threoninamide trifluoroacetate
(S)-1-(L-threonyl-L-prolyl)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)pyrrolidine-2-carboxamide
(S)-N-((2S,3R)-1-amino-3-hydroxy-1-oxobutan-2-yl)-1-((S)-1-((2S,3R)-2-amino-3-hydroxybutanoyl)pyrrolidine-2-carbonyl)pyrrolidine-2-carboxamide
(2s)-1-[(2s)-1-[(2s,3r)-2-amino-3-hydroxybutanoyl]pyrrolidine-2-carbonyl]-n-[(2s,3r)-1-amino-3-hydroxy-1-oxobutan-2-yl]pyrrolidine-2-carboxamide | [Molecular Formula]
C18H31N5O6 | [MDL Number]
MFCD20527320 | [MOL File]
117928-94-6.mol | [Molecular Weight]
413.47 |
| Chemical Properties | Back Directory | [Boiling point ]
844.2±65.0 °C(Predicted) | [density ]
1.370±0.06 g/cm3(Predicted) | [storage temp. ]
?20°C | [solubility ]
DMF: 25 mg/ml; DMSO: 15 mg/ml; Ethanol: 10 mg/ml; PBS (pH 7.2): 5 mg/ml | [form ]
powder | [pka]
12.26±0.45(Predicted) | [color ]
white to tan | [Water Solubility ]
Soluble to 2 mg/ml in water | [Sequence]
Thr-Pro-Pro-Thr-NH2 | [InChIKey]
GIBQQARAXHVEGD-BSOLPCOYSA-N | [SMILES]
C(N)(=O)[C@H]([C@H](O)C)NC(=O)[C@@H]1CCCN1C(=O)[C@@H]1CCCN1C(=O)[C@H]([C@H](O)C)N |
| Questions And Answer(Q&A) | Back Directory | [Uses]
Rapastinel is a novel antidepressant drug approved as an adjunctive therapy for the treatment of treatment-resistant major depressive disorder. It is a centrally active, intravenously administered (non-orally active) amidated tetrapeptide (Thr-Pro-Pro-Thr-NH2) that acts as a selective, weak partial agonist (mixed antagonist/agonist) of an allosteric site at the glycine site of the NMDA receptor complex (Emax ≈ 25%).The drug is a rapid-acting and long-lasting antidepressant as well as robust cognitive enhancer by virtue of its ability to both inhibit and enhance NMDA receptor-mediated signal transduction. |
| Hazard Information | Back Directory | [Biochem/physiol Actions]
GLYX-13 is a glycine-site functional partial agonist (GFPA) selective modulator of the NMDA receptor (NMDAR). It is a brain penetrable tetrapeptide which acts as a positive allosteric modulator of the NMDA receptor, acting via the glycine site. GLYX-13 has been found to be a cognitive enhancer in learning models and is currently in clinical trials as an antidepressant. | [storage]
Store at -20°C |
|
|